AMOÉBA | Sales 2023 | - | Sales 2024 * | - | Capitalization | 22.76M 24.33M 1.95B |
|---|---|---|---|---|---|
| Net income 2023 | -14M -14.97M -1.2B | Net income 2024 * | -4M -4.28M -342M | EV / Sales 2023 | - |
| Net Debt 2023 * | 9.7M 10.37M 831M | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | - |
| P/E ratio 2023 * |
-2.41
x | P/E ratio 2024 * |
-
| Employees | - |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 67.54% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | - | |
Valérie Filiatre
DFI | Director of Finance/CFO | - | - |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 23/06/21 | |
Sylvie Guinard
BRD | Director/Board Member | - | 19/01/22 |
| Director/Board Member | 61 | 16/12/20 |
Amoéba specializes in the development, production and marketing of organic biocide for the treatment of legionella and amoebae in waters. This new disinfecting agent, Biomeba, destroys these pathogens without impact on water systems and the environment.
Sector
Agricultural Chemicals
Calendar
19/09/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +1.19% | 3.58B | |
| -17.77% | 2.21B | |
| -0.69% | 1.8B | |
| -13.26% | 1.85B | |
| -5.70% | 1.6B | |
| -2.11% | 1.27B | |
| -2.91% | 1.1B | |
| -22.97% | 1.02B | |
| -8.05% | 951M |
